Bloomberg

Kodak pivots to drugs after abandoning photography, crypto

Peter Navarro, director of the National Trade Council, arrives at the West Wing of the White House in Washington on July 8, 2020. Foto: Bloomberg/Al Drago

Eastman Kodak Co. is getting another shot at redemption.

The 131-year-old company that once dominated the market for photographic film and made an ill-fated foray into cryptocurrencies is pivoting again. This time, Kodak plans to make ingredients for generic drugs, aided by a $765 million U.S. government loan, the first fruits of a Trump Administration program aimed at bolstering American drug-making capabilities in the age of covid-19...

BRANCHENYT
Læs også